Products and Services
LCT is focused on developing treatments for diseases that have no cure, and a clear, unmet need for improved management.
LCT’s platform technologies, processes and products have enabled a robust research and development pipeline. LCT is working with partners around the world to accelerate and realize the value of its many programs.
DIABECELL is a porcine, insulin-producing cell product for the treatment of Type 1 diabetes. These islet cells are self-regulating and efficiently secrete insulin in the patient’s body. Full info
NTCELL is a choroid plexus cell product with the potential to treat neurodegenerative diseases. These cells help produce cerebrospinal fluid as well as a range of neurotrophins (or nerve growth factors) that have been shown to protect against neuron (nerve) cell death in animal models of disease. Full info
LCT’s microcapsule technology, IMMUPEL™, isolates the transplanted cells from the patient’s immune system and eliminates the need for toxic immunosuppressant drugs. Encapsulation permits oxygen and nutrients to diffuse inwards to maintain cell viability, while secreted cell products are able to exit and exert the desired benefit. Full info
LCT’s encapsulation technology, IMMUPEL™, is based on a patented process which involves wrapping healthy, living cells in a tiny alginate capsule, allowing them to be safely implanted into patients without the need for immunosuppression. These cells act to replace or repair damaged tissue in patients. Full info
The Molecular Diagnostic Laboratory (MDL) of Living Cell Technologies Limited provides high quality rapid diagnostic testing options to veterinary practices across New Zealand and Asia Pacific. Delivering exceptional quality diagnostic results is a touchstone of our laboratory practice. LCT MDL has stringent internal quality control policy, numerous external quality assessment schemes and IANZ accreditation to NZS/ISO 15819:2007. Full info